Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment

Urology

Volumn 68, Issue 2 SUPPL., 2006, Pages 3-8

  Brubaker, Linda ^a   Chapple, Christopher ^b   Coyne, Karin S ^c   Kopp, Zoe ^d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE;

ARTICLE; CLINICAL TRIAL; HUMAN; INFORMATION PROCESSING; INSTRUMENTATION; NOCTURIA; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL ANALYSIS; SYMPTOM; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS; CRESOLS; HEALTH STATUS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; QUALITY OF LIFE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE, STRESS;

EID: 33746873324     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.05.045     Document Type: Article

References (41)

1. Fairclough D.L. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 13 (2004) 115-138
2. Kelleher C. Quality of life and urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynaecol 14 (2000) 363-379
3. Abrams P., Arbitani W., Gajewski J.B., et al. Assessment of treatment outcomes in patients with overactive bladder. importance of objective and subjective measures. Urology 68 suppl 2A (2006) 17-28
4. Willke R.J., Burke L.B., and Erickson P. Measuring treatment impact. a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 25 (2004) 535-552
5. Fitzpatrick R., Davey C., Buxton M.J., et al. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 2 (1998) 1-73
6. Coyne K., Revicki D., Hunt T., et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire. the OAB-q. Qual Life Res 11 (2002) 563-574
7. Abrams P., Kelleher C., Lerr L., et al. Overactive bladder significantly affects quality of life. Am J Manag Care 6 (2000) S580-S590
8. Chapple C.R., and Wein A.J. The urgency of the problem and the problem of urgency in the overactive bladder. BJU Int 95 (2005) 274-275
9. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function. report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003) 37-49
10. Ricci J.A., Baggish J.S., Hunt T.L., et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 23 (2001) 1245-1259
11. Irwin D.E., Milsom I., Kopp Z., et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 97 (2006) 96-100
12. Coyne K., Payne C., Bhattacharyya S., et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder. results from a national community survey. Value Health 7 (2004) 451-459
13. Liberman J.N., Hunt T.L., Stewart W.F., et al. Health-related quality of life among adults with symptoms of overactive bladder. results from a U.S. community-based survey. Urology 57 (2001) 1044-1050
14. Coyne K.S., Zhou Z., Thompson C., et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 92 (2003) 731-735
15. Wyman J.F., Harkins S.W., Choi S.C., et al. Psychosocial impact of urinary incontinence in women. Obstet Gynecol 70 (1987) 378-381
16. Weber A.M., Abrams P., Brubaker L., et al. The standardization of terminology for researchers in female pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct 12 (2001) 178-186
17. Homma Y., and Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin. a randomized, placebo-controlled trial. World J Urol 22 (2004) 251-256
18. Kelleher C.J., Kreder K.J., Pleil A.M., et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 8 (2002) S616-S630
19. Kelleher C.J., Reese P.R., Pleil A.M., et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 8 (2002) S608-S615
20. Kelleher C.J., Cardozo L., Chapple C.R., et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 95 (2005) 81-85
21. Kelleher C.J., Cardozo L.D., Khullar V., et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104 (1997) 1374-1379
22. Brubaker L. Urgency. the cornerstone symptom of overactive bladder. Urology 64 (2004) 12-16
23. Chapple C.R., Artibani W., Cardozo L.D., et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome. current concepts and future prospects. BJU Int 95 (2005) 335-340
24. Dmochowski R., Heit M., and Sand P. The effect of anticholinergic therapy on urgency severity in patients with overactive bladder. clinical assessment of a newly validated tool. [abstract]. Neurourol Urodyn 22 (2003) 411-412
25. Cardozo L., Coyne K.S., and Versi E. Validation of the Urgency Perception Scale. BJU Int 95 (2005) 591-596
26. Brubaker L., and Shull B. EGGS for patient-centered outcomes. Int Urogynecol J Pelvic Floor Dysfunct 16 (2005) 171-173
27. Wiklund I. Assessment of patient-reported outcomes in clinical trials. the example of health-related quality of life. Fundam Clin Pharmacol 18 (2004) 351-363
28. Pleil A.M., Coyne K.S., Reese P.R., et al. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue-the BSW. Value Health 8 suppl 1 (2005) S25-S34
29. Piault E, Evans C, Marcucci G, et al: Patient satisfaction: international development, translatability assessment and linguistic validation of the OAB-S, an overactive bladder treatment satisfaction questionnaire: ISPOR 8th Annual European Congress. Florence, Italy. Value in Health 8(6):A88(PUK36), 2005.
30. Conway K., Acquadro C., Uzun V., et al. Linguistic validation of the overactive bladder questionnaire (OAB-q), OAB-q SF and the overactive bladder-validated 8 (OAB V8) screening questionnaire for this condition in Europe, Asia, North America, and South America. Int Urogynecol J 16 suppl 2 (2005) S103-S104
31. Carlberg A. Patient satisfaction and design of treatment. results from a study of two different ways of treating hypertension. Scand J Prim Health Care 11 (1993) 105-110
32. Cleary P.D., and McNeil B.J. Patient satisfaction as an indicator of quality care. Inquiry 25 (1988) 25-36
33. Ware J.E. How to survey patient satisfaction. Drug Intell Clin Pharm 15 (1978) 892-899
34. Acquadro C., Berzon R., Dubois D., et al. Incorporating the patient's perspective into drug development and communication. an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 6 (2003) 522-531
35. Chassany O., Sagnier P., Marquis P., et al. Patient-reported outcomes. the example of health-related quality of life-a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 36 (2002) 209-238
36. Revicki D.A., Osoba D., Fairclough D., et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9 (2000) 887-900
37. European Agency for the Evaluation of Medicinal Products and Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence (2002) London
38. European Agency for the Evaluation of Medicinal Products and Committee for Proprietary Medicinal Products. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products (2004) London
39. Sloan J.A., Aaronson N., Cappelleri J.C., et al. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 77 (2002) 479-487
40. McHorney C.A., Kosinski M., and Ware J.E. Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview. results from a national survey. Med Care 32 (1994) 551-567
41. Weinberger M., Oddone E.Z., Samsa G.P., et al. Are health-related quality-of-life measures affected by the mode of administration?. J Clin Epidemiol 49 (1996) 135-140